RJA
DXCM icon

Raymond James & Associates’s DexCom DXCM Stock Holding History

Raymond James & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$83.6M Buy
1,247,013
+164,040
+15% +$13.5M 0.05% 314
2024
Q2 		$123M Buy
1,082,973
+51,273
+5% +$6.48M 0.08% 212
2024
Q1 		$143M Buy
1,031,700
+853,743
+480% +$107M 0.1% 187
2023
Q4 		$22.1M Sell
177,957
-143,569
-45% -$14.7M 0.02% 695
2023
Q3 		$30M Sell
321,526
-31,612
-9% -$3.56M 0.03% 530
2023
Q2 		$45.4M Buy
353,138
+29,200
+9% +$3.53M 0.04% 385
2023
Q1 		$37.6M Sell
323,938
-70,023
-18% -$7.84M 0.03% 438
2022
Q4 		$44.6M Sell
393,961
-57,938
-13% -$6.36M 0.04% 380
2022
Q3 		$36.4M Sell
451,899
-30,839
-6% -$2.61M 0.04% 405
2022
Q2 		$36M Buy
482,738
+27,926
+6% +$2.55M 0.04% 408
2022
Q1 		$58.2M Buy
454,812
+25,016
+6% +$2.74M 0.05% 322
2021
Q4 		$57.7M Sell
429,796
-24,340
-5% -$3.5M 0.05% 340
2021
Q3 		$62.1M Buy
454,136
+18,284
+4% +$2.31M 0.06% 295
2021
Q2 		$46.5M Buy
435,852
+243,048
+126% +$23.3M 0.04% 370
2021
Q1 		$17.3M Sell
192,804
-10,184
-5% -$956K 0.02% 731
2020
Q4 		$18.8M Sell
202,988
-129,580
-39% -$11.6M 0.02% 647
2020
Q3 		$34.3M Buy
332,568
+12,104
+4% +$1.26M 0.04% 354
2020
Q2 		$32.5M Buy
320,464
+9,024
+3% +$807K 0.04% 352
2020
Q1 		$21M Buy
311,440
+71,228
+30% +$4.43M 0.03% 444
2019
Q4 		$13.1M Buy
240,212
+33,444
+16% +$1.59M 0.02% 776
2019
Q3 		$7.71M Buy
206,768
+56,344
+37% +$2.19M 0.01% 988
2019
Q2 		$5.63M Sell
150,424
-25,260
-14% -$794K 0.01% 1154
2019
Q1 		$5.23M Buy
175,684
+8,924
+5% +$314K 0.01% 1164
2018
Q4 		$4.99M Buy
166,760
+44,972
+37% +$1.43M 0.01% 1105
2018
Q3 		$4.36M Buy
121,788
+1,304
+1% +$40.4K 0.01% 1304
2018
Q2 		$2.86M Buy
120,484
+6,748
+6% +$143K ﹤0.01% 1539
2018
Q1 		$2.11M Sell
113,736
-33,800
-23% -$500K ﹤0.01% 1664
2017
Q4 		$2.12M Sell
147,536
-140,672
-49% -$1.83M ﹤0.01% 1649
2017
Q3 		$3.52M Sell
288,208
-20,328
-7% -$359K 0.01% 1271
2017
Q2 		$5.64M Buy
308,536
+28,908
+10% +$534K 0.01% 983
2017
Q1 		$5.92M Sell
279,628
-267,848
-49% -$5.23M 0.01% 935
2016
Q4 		$8.17M Buy
547,476
+183,852
+51% +$3.26M 0.02% 729
2016
Q3 		$7.97M Buy
363,624
+145,772
+67% +$3.24M 0.02% 719
2016
Q2 		$4.32M Buy
217,852
+14,984
+7% +$255K 0.01% 930
2016
Q1 		$3.44M Sell
202,868
-22,452
-10% -$375K 0.01% 1004
2015
Q4 		$4.61M Sell
225,320
-19,204
-8% -$400K 0.02% 842
2015
Q3 		$5.25M Sell
244,524
-13,884
-5% -$310K 0.02% 725
2015
Q2 		$5.17M Buy
258,408
+5,996
+2% +$105K 0.02% 800
2015
Q1 		$3.93M Sell
252,412
-776
-0.3% -$11.7K 0.02% 867
2014
Q4 		$3.48M Sell
253,188
-10,052
-4% -$123K 0.02% 858
2014
Q3 		$2.63M Sell
263,240
-5,900
-2% -$60.3K 0.02% 954
2014
Q2 		$2.67M Sell
269,140
-49,368
-15% -$437K 0.02% 939
2014
Q1 		$3.29M Sell
318,508
-47,948
-13% -$496K 0.02% 759
2013
Q4 		$3.24M Sell
366,456
-20,008
-5% -$158K 0.02% 713
2013
Q3 		$2.73M Sell
386,464
-274,836
-42% -$1.74M 0.02% 730
2013
Q2 		$3.71M Buy
+661,300
New +$3.17M 0.04% 540

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Raymond James & Associates's DXCM Position: Q3 2024 in Review

Raymond James & Associates increased its DexCom (DXCM) stake by 15% in Q3 2024, buying an estimated $13.5M and bringing the position to 1,247,013 shares worth $83.6M. The position accounts for 0.05% of the portfolio, ranked #314.

Raymond James & Associates first reported a position in DXCM in Q2 2013 and has held it in 46 quarters since. The position peaked at $143M in Q1 2024. 889 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

  • Raymond James & Associates held 1,247,013 shares of DexCom worth $83.6M as of Q3 2024.
  • Raymond James & Associates bought 164,040 DexCom shares in Q3 2024, an estimated $13.5M.
  • DexCom made up 0.05% of Raymond James & Associates's portfolio in Q3 2024, its #314 holding.
  • Raymond James & Associates first reported a position in DexCom in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's DexCom position peaked at $143M in Q1 2024.
  • 889 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.